u/nadia_nascimento

What does the local patient information leaflet say?

What is the plan if the drift continues for another month?

Correction: that trial measured regain after withdrawal, not failure of the drug during treatment. Very different claim.

How long have you been at goal?

Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.

Correcting myself: I said the regulatory position had not changed and in that jurisdiction it has.

That is a purity figure, not an identity confirmation. Two different tests and only one answers the question asked.

Gently disagree with the self-blame. What you describe is a procedural gap, and the procedure was not written down anywhere for you to follow.

That reads as a warning about a documented supplier and the events you describe are about a shop nobody has any record of.

Dose reduction and interval extension are different interventions. Halving the dose keeps the rhythm and lowers the level; stretching keeps the level and lowers the frequency, with a lower trough.

Is this the first time, or a pattern you can see now?

somebody will read this at the point you were at, and it will help

Appetite returning before the scale moves follows from the mechanism: the appetite effect is the proximal one and weight is the lagging integrated outcome.

Kept the prescription and the receipt for a claim, purely because a thread here told me to. Both were requested.

Is this a cross-border question or a domestic one?

Assumed a prescription would be honoured across the border. It was not, and the rules are clear once you actually read them.

Lost money to a shop that had nothing verifiable on file anywhere. Posting so that somebody searching that name finds this.

Sent a vial to Janoshik: 98.9% against a claimed 98.5%, with the mass confirming the sequence. Both halves mattered to me.

the same product has different names and pack sizes across the union

Paid for identity confirmation rather than just purity for the first time here. Worth it, and it is not the default on most certificates.

Push back: "no reported harms" in a literature with almost no human trials is not a safety finding.

plan the maintenance phase before you need it

somebody will read this at the point you were at, and it will help

I would not extrapolate a mechanism from a model system to a person in one step, which is what that comment does.

plan the maintenance phase before you need it

Same. The thing that went wrong for me was procedural and boring and it cost me a lot.

Interval stretching changes the exposure profile: with a week-long half-life, moving to ten or twelve days lowers trough concentration more than it lowers average exposure. That is why appetite return is often the first thing noticed.

stretching the interval is not the same as reducing the dose

Body weight varies by a couple of kilos over days in stable people through fluid, glycogen and gut content. A range is not a trend.

find the dose that holds, then stop optimising

Disagree with chasing the last stretch by going up. You are trading a real side-effect cost for a number you chose arbitrarily.

Yes. The habits have to outlive the dose or the maintenance phase is just a countdown.

Careful. Regulatory status differs by jurisdiction and has changed; a confident global statement is going to be wrong somewhere.

Contemporaneous notes matter most in exactly the situations where people are least inclined to write them. Memory reorganises a bad fortnight into a tidier story with a clearer villain.

Cross-border prescription recognition exists under EU rules but is conditional and narrower than commonly assumed, with requirements about the prescription’s form and content.

buy small first is the lesson that keeps being learned expensively

coming back to say you were wrong takes more than being right did